Drug Development

Each year many new prescription drugs are approved by the Food and Drug Administration (FDA). The process of developing and bringing new drugs to market is important for primary care physicians to understand. A drug must undergo rigorous testing prior to marketing to and medical use by the general public. The process starts with preclinical testing. For drugs that appear safe, an investigational new drug application is filed with the FDA. If approved, clinical trials begin with phase 1 studies that focus on safety and pharmacology. Phase 2 studies examine the effectiveness of the compound. Phase 3 is the final step before submitting a new drug application (NDA) to the FDA. An NDA contains all the information obtained during all phases of testing. Phase 4 studies, or postmarketing studies, are conducted after a product is approved. Recent changes in legislation have streamlined the approval process. Critics contend that these changes have compromised public safety, resulting in the need to recall several products from the market. Proponents claim that changes in the approval process help patients with debilitating diseases, such as acquired immunodeficiency syndrome, that were previously denied critical medication because of bureaucratic regulations.

The worldwide market for medication disclosure in pharmaceuticals came to about $25.0 billion in 2013. This market is relied upon to reach $29.6 billion in 2014 and $79.8 billion in 2019, with a compound yearly development rate (CAGR) of 22.0% for the time of 2014 to 2019.

 

  • Discovery and Development
  • Preclinical Research
  • Clinical Research
  • FDA Review
  • Drug Development Research
  • Drug Characterisation
  • Drug Designing and Targeting

Related Conference of Drug Development

October 25-26, 2019

14th International Conference on Biopharma and Biotherapeutics

| Copenhagen, Denmark
October 23-24, 2019 | Copenhagen, Denmark

12th Pharma Congress

September 11-12, 2019

2nd Annual Pharmaceutical Biotechnology Congress

Singapore
November 11-12, 2019

20th Annual Pharma Middle East Congress

Renaissance Polat Istanbul Hotel | Istanbul, Turkey
November 18-19, 2019

European Congress on Nanomedicine and Pharmaceutical Nanotechnology

Prague, Czech Republic
November 18-19, 2019

European Conference on Pharmacovigilance & Drug Safety

Prague, Czech Republic
December 02-03, 2019

15th Annual Congress on Pharmacology and Toxicology

Paris, France
February 12-13, 2020

14th Global Pharmacovigilance and Clinical Trials Summit

Sydney, Australia
February 12-13, 2020

2nd International Conference on Biosimilars & Pharmaceuticals

Auckland, New Zealand
March 25-26, 2020

23rd Asia Pacific Pharma Congress

Singapore
April 01-02, 2020

13th European Biosimilars Congress 2020

London, UK
April 09-10, 2020

World Pharma Expo

Bangkok, Thailand
April 27-28, 2020

5th Pharmaceutical Chemistry Conference

Prague, Czech Republic
April 27-28, 2020

7th European Biopharma Congress

Prague, Czech Republic
May 06-07, 2020

15th Annual Meet on Euro Ethnopharmacology

Prague | Czech Republic
May 18-19, 2020

30th Annual European Pharma Congress

Berlin, Germany
May 27- 28, 2020

14 th World Drug Delivery Summit

| London, UK
August 26-27, 2020

33rdWorld Congress on Pharmacology

Barcelona, Spain
September 10-11, 2020

World Congress on Rare Diseases & Orphan Drugs

| Prague, Czech Republic
September 21-22, 2020

35th World Pharmacology and Toxicology Forum

Tokyo, Japan
October 19-20, 2020

Innovation in Drug Design Techniques and Pharmacology

| Paris, France
December 02-03, 2020

International Conference onBiotechnology and Healthcare

Auckland, Newzealand
December 06-07, 2021

22nd Pharma Middle East Congress

Dubai, UAE

Drug Development Conference Speakers

Recommended Sessions

Related Journals

Are you interested in